Evidence map›Paper›PMID 42005708›Full record

ReviewInternational journal of nanomedicine2026

Deep Tumor Penetration Using Nanoparticle Delivery Systems: Programmed Design Strategies and Emerging Evaluation Platforms.

Mahsa Javan, Deniz Ajabi Zareian, Solmaz Mojarad-Jabali

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mahsa JavanTabriz University of Medical Sciences, Tabriz, Iran.
Deniz Ajabi ZareianTabriz University of Medical Sciences, Tabriz, Iran.
Solmaz Mojarad-JabaliPharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complex architecture of solid tumors, including dense extracellular matrix and abnormal vasculature, impedes effective nanoparticle (NP) delivery. Conventional NPs often fail to penetrate deeply due to their fixed size, rapid clearance, and poor tumor retention. Unlike previous reviews that focus solely on physicochemical properties, this article critically evaluates "programmed" delivery strategies that dynamically adapt to physiological barriers. Size-transformable nanocarriers offer a promising solution by remaining large during circulation to exploit the enhanced permeability and retention (EPR) effect, then shrinking in response to tumor-specific stimuli (eg, low pH, high glutathione, or enzymatic activity), thereby improving tumor penetration and drug release This review highlights recent advances in overcoming these obstacles, with a focus on programmed delivery strategies NPs with a size-switching technique degrade upon reaching the tumor site, allowing for deeper penetration. Surface modification enhances interactions with the tumor microenvironment (TME), whereas ligands improve target selectivity and tumor cell uptake, and altering the NP form improves their delivery and distribution within tumors. Uniquely, the review bridges the gap between design and evaluation by discussing emerging experimental platforms such as 3D tumor models and microfluidic chips. Finally, it examines the growing role of artificial intelligence (AI) and in silico modeling in optimizing NP design, offering insights into precision nanomedicine.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsNanoparticle Drug Delivery SystemNanoparticlesNeoplasmsAnimalsArtificial IntelligenceHumansNanomedicineTumor MicroenvironmentAntineoplastic AgentsNanoparticle Drug Delivery Systemdrug deliverynanoparticlesmart systemstumor microenvironmenttumor penetration

Identifiers

PMID42005708
PMCPMC13091639

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.